Abeona Therapeutics Inc. (ABEO)

NASDAQ: ABEO · IEX Real-Time Price · USD
3.28
+0.24 (7.89%)
At close: Oct 3, 2022 4:00 PM
3.38
+0.10 (3.05%)
After-hours: Oct 3, 2022 7:38 PM EDT
7.89%
Market Cap 19.52M
Revenue (ttm) 4.70M
Net Income (ttm) -86.60M
Shares Out 5.95M
EPS (ttm) 38.68
PE Ratio 0.08
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 460,408
Open 3.10
Previous Close 3.04
Day's Range 3.01 - 3.34
52-Week Range 0.27 - 27.75
Beta 1.08
Analysts Buy
Price Target 15.98 (+387.2%)
Earnings Date Nov 14, 2022

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorder... [Read more...]

Industry Biotechnology
IPO Date Sep 19, 1980
CEO Joao Siffert
Employees 90
Stock Exchange NASDAQ
Ticker Symbol ABEO
Full Company Profile

Financial Performance

In 2021, ABEO's revenue was $3.00 million, a decrease of -70.00% compared to the previous year's $10.00 million. Losses were -$84.94 million, 0.83% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is 15.98, which is an increase of 387.20% from the latest price.

Price Target
$15.98
(387.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside c...

1 week ago - GlobeNewsWire

Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference

NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel disc...

2 weeks ago - GlobeNewsWire

Abeona Therapeutics Reports Second Quarter 2022 Financial Results

Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023

1 month ago - GlobeNewsWire

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 infor...

2 months ago - GlobeNewsWire

Abeona Therapeutics to Present at the Jefferies Healthcare Conference

NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is schedule...

3 months ago - GlobeNewsWire

Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule

NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an...

4 months ago - GlobeNewsWire

Abeona Therapeutics Reports First Quarter 2022 Financial Results

Disposition of MPS programs to reduce operating expenses and  extend projected cash runway into 2Q 2023

4 months ago - GlobeNewsWire

Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Ret...

NEW YORK and CLEVELAND, Ohio, May 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced the presentation of new precli...

4 months ago - GlobeNewsWire

Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual ...

NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on AAV204, a...

5 months ago - GlobeNewsWire

Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock

NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that it has entered into a securit...

5 months ago - GlobeNewsWire

Abeona Therapeutics Announces Strategy Update and 2021 Financial Results

EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained FDA alignment on CMC requirements for EB-101 including characterization a...

6 months ago - GlobeNewsWire

Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

NEW YORK and CLEVELAND, March 28, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief E...

6 months ago - GlobeNewsWire

Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEB

Topline data from VIITAL™ expected in the third quarter of 2022 Topline data from VIITAL™ expected in the third quarter of 2022

6 months ago - GlobeNewsWire

Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing

Abeona Therapeutics (ABEO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement am...

8 months ago - Zacks Investment Research

Abeona Therapeutics Issues Letter to Shareholders

NEW YORK and CLEVELAND, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to shareholders.

9 months ago - GlobeNewsWire

Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants

NEW YORK and CLEVELAND, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the pricing of its underwritten pub...

9 months ago - GlobeNewsWire

Abeona Therapeutics Announces Public Offering of Common Stock and Warrants

NEW YORK and CLEVELAND, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and sell s...

9 months ago - GlobeNewsWire

Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a Turnaround

Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

10 months ago - Zacks Investment Research

Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Ed...

NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second annua...

10 months ago - GlobeNewsWire

Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conf...

NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the company'...

10 months ago - GlobeNewsWire

Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference

NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Ex...

10 months ago - GlobeNewsWire

Abeona Therapeutics Reports Third Quarter Financial Results

Phase 3 VIITAL™ study on track to complete enrollment in first quarter 2022 with final patients identified and under screening

10 months ago - GlobeNewsWire

Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit

NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., ...

11 months ago - GlobeNewsWire

Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses

NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously dis...

11 months ago - GlobeNewsWire

Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality

NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice...

11 months ago - GlobeNewsWire